Atogepant

Atogepant is a small molecule calcitonin gene-related peptide (CGRP) receptor antagonist approved for the preventive treatment of migraine in adults. It belongs to a class of medications called gepants.

Mechanism of Action: Atogepant works by blocking the CGRP receptor. CGRP is a neuropeptide that is believed to play a significant role in the pathophysiology of migraine. By antagonizing the CGRP receptor, atogepant reduces the ability of CGRP to bind and activate the receptor, thereby potentially reducing the frequency of migraine headaches.

Indications: Atogepant is specifically indicated for the preventive treatment of migraine in adults.

Administration: Atogepant is administered orally.

Adverse Effects: Common adverse effects associated with atogepant include nausea, constipation, and fatigue. Other side effects are possible.

Contraindications: Atogepant may have specific contraindications based on individual patient factors. Consulting with a healthcare professional is necessary to determine suitability.

Pharmacokinetics: Atogepant's absorption, distribution, metabolism, and excretion have been studied and characterized.

Drug Interactions: Atogepant may interact with other medications. It is important to inform healthcare providers of all medications being taken before starting atogepant.

Pregnancy and Lactation: The use of atogepant during pregnancy and lactation should be discussed with a healthcare provider, as the risks and benefits need to be carefully considered.

Regulatory Approval: Atogepant has received regulatory approval from health authorities, such as the U.S. Food and Drug Administration (FDA), for the specified indication.

Further Research: Ongoing research continues to evaluate the long-term efficacy and safety of atogepant in the preventive treatment of migraine.